Related Experiment Video
Updated: Aug 4, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Inherited disorders of HDL metabolism and atherosclerosis
G Kees Hovingh1, Eric de Groot, Wim van der Steeg
1Department of Vascular Medicine, Academic Medical Center, AZ Amsterdam, The Netherlands.
Insights
Genetic disorders affecting high-density lipoprotein (HDL) metabolism reveal varying atherosclerosis risks. Mutations in apoA-I, ABCA1, and LCAT accelerate atherosclerosis, while cholesteryl ester transfer protein mutations do not, informing targeted therapies.
Area of Science:
- Cardiovascular Genetics
- Lipid Metabolism
- Atherosclerosis Research
Background:
- Genetic disorders of HDL metabolism are rare, complicating atherosclerosis risk assessment.
- Epidemiological studies link low HDL cholesterol to increased coronary artery disease risk.
- Carotid artery ultrasound imaging aids risk assessment in hereditary hypo- and hyperalphalipoproteinemia.
Purpose of the Study:
- To comprehensively summarize the assessment of atherosclerosis risk in individuals with genetic HDL metabolism disorders.
- To compare atherosclerosis progression in carriers of mutations in apolipoprotein A-I (apoA-I), ATP binding cassette AI (ABCA1), lecithin: cholesterol acyltransferase (LCAT), and cholesteryl ester transfer protein (CETP).
Main Methods:
- Direct comparison of carotid intima-media thickness (CIMT) data from individuals with specific genetic mutations.
- Analysis of atherosclerosis progression in carriers versus family controls.
Main Results:
- Mutations in apoA-I, ABCA1, and LCAT are associated with significantly accelerated atherosclerosis progression.
- Carriers of apoA-I mutations showed the most pronounced atherosclerosis acceleration.
- Heterozygosity for CETP mutations did not result in increased intima-media thickness progression compared to controls.
- Hyperalphalipoproteinemia due to CETP loss-of-function showed unaltered atherosclerosis progression.
Conclusions:
- Hypoalphalipoproteinemia linked to apoA-I, ABCA1, and LCAT mutations increases atherosclerosis progression.
- Hyperalphalipoproteinemia due to CETP dysfunction is not associated with accelerated atherosclerosis.
- Findings aid in prioritizing antiatherogenic therapies aimed at increasing HDL cholesterol.
Purpose Of Review:
Genetic disorders of HDL metabolism are rare and, as a result, the assessment of atherosclerosis risk in individuals suffering from these disorders has been difficult. Ultrasound imaging of carotid arteries has provided a tool to assess the risk in hereditary hypo and hyperalphalipoproteinemia. This review gives a comprehensive summary.
Recent Findings:
Epidemiological studies have unequivocally shown that HDL cholesterol levels are inversely related to coronary artery disease risk, but the literature concerning genetic disorders of HDL metabolism provides less convincing information. Fortuitously, we were able to directly compare carotid intima media thickness data of substantial numbers of individuals with mutations in either apolipoprotein A-I (apoA-I), ATP binding cassette AI (ABCA1), lecithin: cholesterol acyltransferase (LCAT) or cholesteryl ester transfer protein. These data show that carriers of an apoA-I mutation exhibit the most pronounced accelerated atherosclerosis compared with those carrying mutations in ABCA1 and LCAT. Heterozygosity for a non-sense mutation in cholesteryl ester transfer protein did, by contrast, not distinguish carriers from controls in terms of intima media thickness progression. We will discuss these results in the context of the current literature.
Summary:
Intima media thickness studies have provided evidence that hypoalphalipoproteinemia due to mutations in apoA-I, ABCA1, and LCAT is associated with increased progression of atherosclerosis. In contrast, hyperalphalipoproteinemia as a result of loss of cholesteryl ester transfer protein function is associated with unaltered atherosclerosis progression compared with family controls. This insight is of interest, since it can assist in the prioritizing of antiatherogenic therapy by increasing HDL cholesterol levels.
Related Concept Videos
Sex-linked Disorders
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Atherosclerosis I: Introduction
Atherosclerosis III: Management

